The Time Toxicity of Cancer Treatment

Cited by (356)

Items 101–200 of 356

1. The weight of time: experience of time toxicity among advanced cancer patients and their family caregivers—a qualitative study
   Jie Jing, Mohan Li, Yehao Rui, Danruo Wang, Qiuchen Zhu, Ling Yuan · 2025 · Supportive Care in Cancer
2. Tumor Is Not the Only Target: Ensuring Equitable Person-Centered Supportive Care in the Era of Precision Medicine
   Ramy Sedhom, Gleneara E. Bates-Pappas, Jill Feldman, Ronit A. Elk, Arjun Gupta, Michael Jordan Fisch, Enrique Soto‐Pérez‐de‐Celis · 2024 · American Society of Clinical Oncology Educational Book
3. Disparities in the availability of and access to neuro-oncology trial-supporting infrastructure in the United States
   Yeonju Kim, Terri S. Armstrong, Mark R. Gilbert, Orieta Celiku · 2024 · JNCI Journal of the National Cancer Institute
4. Sequencing bispecific antibodies and CAR T cells for FL
   David A. Russler‐Germain, Nancy L. Bartlett · 2024 · Hematology
5. Characterizing treatment burden during neoadjuvant therapy for patients with gastrointestinal cancer: A mixed methods analysis
   Natalie M. Bath, Angela Sarna, Marilly S. Palettas, Christina Monsour, Lena Stevens, Heena P. Santry, Aslam M. Ejaz, Alex Kim, Timothy Michael Pawlik, Jordan M. Cloyd · 2023 · Journal of Surgical Oncology
6. Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations
   Arjun Gupta, Michelle Tregear, Makala B. Pace, Rachel Isaksson Vogel · 2024 · JCO Oncology Practice
7. An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases
   Marc Kerba, Richard De Abreu Lourenço, Arjun Sahgal, Rafael Emilio de Feria Cardet, Shankar Siva, Keyue Ding, Sten D. Myrehaug, Laura Masucci, Michael Brundage, Wendy R. Parulekar · 2024 · International Journal of Radiation Oncology*Biology*Physics
8. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer
   Luke Steventon, Kenneth K. C. Man, Shibani Nicum, Rowan E. Miller, Shira Peleg Hasson, Samixa Shah, Michael Baser, Emma Kipps, Martin David Forster, Ofran Almossawi et al. · 2024 · The Oncologist
9. Days at Home After Cancer Surgery: Impact of Area Deprivation and Association with Long-Term Outcomes
   Odysseas P Chatzipanagiotou, Mujtaba Khalil, Selamawit Woldesenbet, Giovanni Catalano, Timothy Michael Pawlik · 2024 · Annals of Surgical Oncology
10. The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
    Capucine Baldini, Anna Rachelle Mislang, Kwok‐Leung Cheung, Sophie Pilleron, H. Wildiers, Siri Rostoft, Nina Rosa Neuendorff, Maxime Frélaut, R. Kanesvaran, D. Papamichael et al. · 2026 · ESMO Open
11. Optimizing care in early phase cancer trials: The role of palliative care
    Fionnuala Crowley, Richard Stephen Sheppard, Stephanie Lehrman, Eve Easton, Thomas Urban Marron, Deborah B. Doroshow, Debora Afezolli · 2024 · Cancer Treatment Reviews
12. Scope, Findability, and Quality of Information About Music-Based Interventions in Oncology: Quantitative Content Analysis of Public-Facing Websites at National Cancer Institute–Designated Cancer Centers
    Carol Ann Blank, Sarah Biedka, Abigail Montalmant, Katelyn Saft, Miranda Lape, Kate Mao, Joke Bradt, Kevin T. Liou · 2024 · JMIR Cancer
13. Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer
    Devon K. Check, Samir S. Soneji, Harvey Jay Cohen, Andrea C. Des Marais, Katie Fitzgerald Jones, Charles E. Gaber, Jessica S. Merlin, Amy O’Regan, Nicole M. Fergestrom, Lauren E. Wilson et al. · 2025 · JNCI Journal of the National Cancer Institute
14. Logistic and time burdens reported by gynecologic and breast cancer survivors
    Allison C. Dona, Aisha Ambo, Patricia I. Jewett, Katherine A. Brown, Helen Parsons, Arjun Gupta, Deanna Gek Koon Teoh, Anne Hudson Blaes, Rachel Isaksson Vogel · 2025 · BMC Women s Health
15. Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care
    Whitney Victoria Johnson, Sai Sudha Valisekka, Obafemi O. Ogunleye, Samuel Xavier Stevens, Manju George, Allison Breininger, Michael Anne Kyle, Christopher M. Booth, Timothy Paul Hanna, Rachel Isaksson Vogel et al. · 2025 · Supportive Care in Cancer
16. What Is Ailing Oncology Clinical Trials? Can We Fix Them?
    Abhenil Mittal, Sara E. Moore, Vishal Navani, Di Jiang, David J. Stewart, Geoffrey Liu, Paul Wheatley‐Price · 2024 · Current Oncology
17. The feasibility and acceptability of home phlebotomy for patients with cancer
    Erin Mary Bange, Camila Bernal, Kemi L. Bolutayo Gaffney, Jill Ackerman, David Kwong, Jithin Thomas, Bobby Daly · 2024 · JNCI Cancer Spectrum
18. Factors Associated With Default of Treatment and Follow-Up Among Patients With Cancer: A Cross-Sectional Study From a Lower-Middle-Income Country
    Deepak Sundriyal, Mayank Kapoor, Preeti Antil, Sweety Gupta, Parmod Kumar, Ujjawal Kumar Shriwastav, Amit Sehrawat · 2024 · JCO Global Oncology
19. A Population-Based Cohort Study of Glioblastoma (World Health Organization Grade 4 Gliomas) in Ontario: Continued Improvement in Care over 25 Years
    Shervin Taslimi, Susan B. Brogly, Timothy Paul Hanna, Jonas P. Shellenberger, Marlo Whitehead, Ryan D. Alkins · 2025 · World Neurosurgery
20. Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors
    Erin Mary Bange, Kerry Q. Coughlin, Wenrui Li, Elizabeth Moriarty, Timothy J. Brown, Lawrence N. Shulman, Ronac Mamtani · 2022 · JAMA Network Open
21. Quantifying days at home in patients with cirrhosis: A national cohort study
    Hirsh Elhence, Jennifer L. Dodge, Albert John Farias, Brian P. Lee · 2023 · Hepatology
22. Surveillance With Serial Imaging and CA 19-9 Tumor Marker Testing After Resection of Pancreatic Cancer
    Minerva Nong, Devanshi Dove, Dawn A. Fischer, Kathryn Cunningham Hourdequin, Gregory H. Ripple, Manik A. Amin, Elizabeth Boutin McGrath, Bassem I. Zaki, Kerrington D. Smith, Gabriel A. Brooks · 2023 · American Journal of Clinical Oncology
23. Cardiovascular risk in cancer patients treated with immune checkpoint inhibitors: challenges and future directions
    Sean Tan, Adam J. Nelson, Rahul G. Muthalaly, Satish Ramkumar, Joshua Hamilton, Nitesh Nerlekar, Eva Segelov, Stephen James Nicholls · 2024 · European Journal of Preventive Cardiology
24. Enhancing Patient Retention in Clinical Trials—Strategies for Success
    Dame W. Idossa, Shruti Rajesh Patel, Narjust Florez · 2023 · JAMA Oncology
25. Geographic Access to Radiation Therapy Services in Canada
    Yang Y. Xu, Oluwaseun Davies, Shaun K. Loewen · 2025 · International Journal of Radiation Oncology*Biology*Physics
26. Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical Trials
    Brooke E. Wilson, Elizabeth A. Eisenhauer, Christopher M. Booth · 2024 · JAMA
27. Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life
    Daniel Sentana‐Lledo, Amelia Barnett, David Johnson Einstein, Arjun Gupta, Alicia Katherine Morgans · 2025 · The Oncologist
28. Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
    Nóra Rebeka Jávorniczky, Olga Grishina, Inga Hund, Milena Pantić, Dietmar Pfeifer, Claudia Schmoor, Johanna M. Thomas, Justus Duyster, Heiko Becker, Michael Lübbert · 2023 · Clinical Epigenetics
29. Optimizing the doses of cancer drugs after usual dose finding
    Garth William Strohbehn, Walter Michael Stadler, Philip S. Boonstra, Mark J. Ratain · 2023 · Clinical Trials
30. A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23–05)
    Siobhán Gaynor, Yvonne O’Meara, Emer Mulvaney, Rachel J. Keogh, Catherine Weadick, Frances K. Duane, Ann Mc Brien, Helen Greally, Mary Jane O’Leary, Ieva Teiserskyte et al. · 2024 · The Breast
31. Common sense cancer care for older adults: Outcomes that matter
    Christopher Frank, Bishal Gyawali, Christopher M. Booth · 2023 · Journal of the American Geriatrics Society
32. Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial
    Santosh kumar Chellapuram, Santosh Kumar Kn, Manraj Singh Sra, Rupak Kumar Giri, Deepam Pushpam, Atul Batra, Sreenivas Vishnubhatla, Shuvadeep Ganguly, Sameer Bakhshi · 2025 · EClinicalMedicine
33. Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis
    Ezequiel Mauro, Marco Sanduzzi‐Zamparelli, Tamara Saurí, Alexandre Soler, Gemma Iserte, Marta Fortuny, Alejandro Forner · 2024 · Cancers
34. Temporal trends in time toxicity of R-CHOP: a nationwide hospital-based database analysis in Japan
    Hiroaki Araie, Tomohisa Seki, Akira Okada, Toshimasa Yamauchi, Masaomi Nangaku, Takashi Kadowaki, Kazuhiko Ohe, Takahiro Yamauchi, Satoko Yamaguchi · 2025 · Supportive Care in Cancer
35. Tensions of time at the end (of life)
    Alex F. Broom, Katherine Kenny, Nadine Ehlers, Henrietta Byrne, Phillip D. Good · 2025 · Social Science & Medicine
36. Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study
    Sana Kagalwalla, Alexander K. Tsai, Michelle Tregear, Andrea Maranda, Dame W. Idossa, Anne Hudson Blaes, Helen M. Parsons, Rachel Isaksson Vogel, Arjun Gupta · 2025 · Journal of Cancer Policy
37. Ethical considerations for hematologic precursor conditions
    Eric C. Blackstone, Lachelle Dawn Weeks, Amy Elizabeth Dezern, Gregory Alan Abel · 2025 · Blood Advances
38. Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study
    Sharada Mailankody, Divyashree Kotian, Karthik Udupa, Ananth Pai, Prajna Shetty, Vasudeva Guddattu, Prasanth Ganesan · 2025 · BMJ Supportive & Palliative Care
39. Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study
    Udit Nindra, Joanne Tang, Jun Hee Hong, Joseph Descallar, Martin Hong, Andrew John Killen, Priyadarshini Dubey, Jeneen Attaullah, Grace Scott, Adam James Cooper et al. · 2025 · JCO Oncology Practice
40. Management of pain in cancer patients— lessons from practices during the COVID-19: a qualitative study of cancer care providers’ perspectives
    Georgina Cornall, Emma Zhao, Tim Luckett, Ertugrul Erciyas, David Monck, Paul A. Glare, Andy Yi-Yang Wang, Yi‐Ching Lee · 2024 · BMC Health Services Research
41. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
    Esther J. Beck, Alexander Dean Sherry, Marcus Alexander Florez, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Avital M. Miller, Adina H. Passy, Gabrielle S. Kupferman, Roshal R. Patel et al. · 2024 · Cancer Research Communications
42. Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer
    Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih · 2024 · Clinical Colorectal Cancer
43. Time’s up: the urgency to investigate time toxicity in patients with genitourinary malignancies
    Daniel Sentana‐Lledo, Alicia Katherine Morgans · 2024 · Therapeutic Advances in Medical Oncology
44. Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
    Michael Karremann, Thomas Perwein, Andre Oscar von Bueren, Gerrit H. Gielen, Martin Benesch, Gunther Nussbaumer, Lea Lydia Friker, Andreas Waha, Dominik Sturm, David Jones et al. · 2025 · EJC Paediatric Oncology
45. Was Unstable Medicaid Coverage Among Older Medicare Beneficiaries Associated With Worse Clinical Outcomes? Evidence From the Delivery of Breast Cancer Care
    Xuanzi Qin, Peter J. Huckfeldt, Jean Marie Abraham, Douglas Yee, Beth A Virnig · 2023 · Medical Care
46. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia
    Shai O. Shimony, Marlise Rachael Luskin · 2023 · Clinical Lymphoma Myeloma & Leukemia
47. Maryland’s Global Budget Revenue Payment Model and Shifts in the Surgical Site of Care Among Medicare Beneficiaries
    Yu-Li Lin, Bradley J. Herring, Alexander Melamed, Abbas M. Hassan, Laura A. Petrillo, Nancy Lynn Keating, Anaeze Chidiebele Offodile · 2024 · Annals of Surgery
48. Health care policies, drug costs, and time toxicities in biologics for HER2-positive breast cancer: cost minimization analysis of direct and indirect costs
    Jia Li Low, R.S.J. Wong, Zhi Yao Chan, S.C. Lee · 2025 · ESMO Real World Data and Digital Oncology
49. Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank
    Sean Khozin, Nancy A Dreyer, Dominic Galante, Raymond Liu, Peter Neumann, Nathan Coleman Nussbaum, Joyce O’Shaughnessy, Debra A. Patt, Mothaffar Fahed Rimawi, Hope S. Rugo et al. · 2025 · Advances in Therapy
50. The association of health care contact days with economic measures in the CCTG LY.12 trial
    Arjun Gupta, Tyler W. Thomas, Annette E. Hay, Michael Crump, Marina Djurfeldt, Matthew C. Cheung, Anca A. Prica, Lois E. Shepherd, Bingshu E. Chen, Christopher M. Booth · 2025 · The Oncologist
51. Immunotherapy for precision medicine in colorectal cancer
    Miao Cao, Michael Y. Xu, Zinah Aqeel Bairmani, Babar Bashir, Scott Arthur Waldman, Adam Eugene Snook · 2025 · Expert Review of Precision Medicine and Drug Development
52. Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care
    Kendall Lin, Sana Kagalwalla, Arjun Gupta · 2025 · Current Treatment Options in Oncology
53. How Important is Healthcare-Contact Time to Systemic Treatment Decision-Making in Advanced Gastrointestinal Cancers: Developing Attributes to Include in a Discrete Choice Experiment
    Samuel Xavier Stevens, Ella El-Katateny, Isaac Yeboah Addo, Deborah J. Street, Christopher M. Booth, Joanne Shaw, Janette L. Vardy, Richard De Abreu Lourenço · 2025 · Patient
54. Time toxicity and shared decision‐making in cerebral palsy
    David Benjamin Frumberg, Paige Church, Nathan Rosenberg · 2025 · Developmental Medicine & Child Neurology
55. Large language models for toxicity extraction in oncology trials: A real-world benchmark in prostate radiotherapy
    Federico Mastroleo, Mariana Borras-Osorio, Shiv P. Patel, Sarah Peterson, Renthony Wilson, Mi Zhou, Satomi Shiraishi, Anthony Foong, David M. Routman, Mark Raymond Waddle · 2025 · Radiotherapy and Oncology
56. A novel patient-centered outcome in cancer care, days at home: a scoping review and guide for its future use
    Tiago Ribeiro, Adom Bondzi‐Simpson, Alyson L Mahar, Angela Jerath, Victoria Barabash, Frances C. Wright, Ekaterina Kosyachkova, Julie M. Deleemans, Natalie G. Coburn, Julie I. Hallet · 2026 · Supportive Care in Cancer
57. Physician-complementing artificial intelligence in haematology: ushering in a new era
    Junren Chen, Robert Peter Gale · 2026 · Leukemia
58. Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study
    Anna Minchom, Byoung Chul Cho, Natasha B. Leighl, Melissa L. Johnson, Joshua K. Sabari, Se-Hoon Lee, Ki Hyeong Lee, Yu Jung Kim, Rachel E. Sanborn, Bert H. O’Neil et al. · 2026 · Clinical Lung Cancer
59. Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide
    Jacqueline Theresa Brown, Bassel Nazha, Anna C. Ferreira, Kent E. Armeson, Elizabeth Goodwin Hill, Besim Öğretmen, Shikhar Mehrotra, Alan Brisendine, George Magrath, Terry F. Plasse et al. · 2026 · Cancer Medicine
60. Time toxicity of patients with cancer enrolled in clinical trials: a systematic review and meta-analysis
    Ronald Chow, James H. B. Im, Georgia Catherine Richards, Camilla Zimmermann, Carl Heneghan · 2026 · BMJ Supportive & Palliative Care
61. Enhanced Telehealth in Prostate Cancer
    Erin Mary Bange, Anne S. Reiner, Christine Liebertz, Charlotte Diane Malling, Gilad J. Kuperman, Bobby Daly, Susan C. Chimonas, Katherine Marcinkowski, Sahil D. Doshi, Fernanda C. G. Polubriaginof et al. · 2026 · JAMA Network Open
62. Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors.
    Matthew T. McMillan, Annemarie Fernandes Shepherd, Minglei Kang, Liyong Lin, Narek Shaverdian, Abraham Jing-Ching Wu, Daphna Y. Gelblum, Nitin Ohri, Stanislav Lazarev, Lee Xu et al. · 2023 · PubMed Central
63. Advancing a telehealth and cancer control research agenda at the US National Cancer Institute
    Robin C. Vanderpool, Abigail Muro, Roxanne E. Jensen · 2024 · JNCI Monographs
64. Factors Guiding Clinical Decision‐Making in Genitourinary Oncology
    Marie Wosny, Stefanie Aeppli, Stefanie Fischer, Tobias Peres, Christian Alexander Rothermundt, Janna Hastings · 2024 · Cancer Medicine
65. In-Center Hemodialysis and Patient Travel Time in Aotearoa New Zealand: A Nationwide Geospatial and Data Linkage Study
    Johanna M Birrell, Angela Claire Webster, Nicholas Cross, Andrew J. Kindon, Matthew Hobbs, James Hedley, Tim Driscoll, Nicole Louise De La Mata · 2024 · Kidney International Reports
66. A Text Message Intervention to Minimize the Time Burden of Cancer Care
    Erin Mary Bange, Kerry Q. Coughlin, Wenrui Li, Timothy J. Brown, Daniel Ragusano, Eesha Balar, Dhivya Arasappan, Michelle Nnaji, E.J. Kim, Corey Alban et al. · 2025 · NEJM Catalyst
67. End points and outcomes in follicular lymphoma: what should we measure, how, and why?
    Mengyang Di, Matthew John Maurer, Christopher R. Flowers · 2025 · Blood
68. Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
    Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, Martin Kaatz, Ulrike Leiter, Bastian Schilling, Patrick Andres Maximilian Terheyden, Jessica C. Hassel, Michael Sachse, Jens Ulrich et al. · 2025 · Journal of the European Academy of Dermatology and Venereology
69. Improving the Dosing Schedules of Targeted Anticancer Agents
    Dominique Levêque · 2025 · Pharmaceuticals
70. Personalized palliative care for older adults with cancer: A call for action on oncogeriatric palliative care
    Gabor Istvan Liposits, Mark A Baxter, Alana Brown-Kerr, Shane O’Hanlon · 2025 · Journal of Geriatric Oncology
71. Clinical outcomes in patients with metastatic castrate‐resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case–control study
    Ali T. Arafa, Leah R. Blader, Karan N. Ramakrishna, Jeff A. Engle, Charles J. Ryan, Nicholas A. Zorko, Gautam Gopalji Jha, Emmanuel S. Antonarakis · 2023 · The Prostate
72. Curing using the minimal – Strategies for treatment reduction in childhood acute lymphoblastic leukemia
    Bernice Ling Zhi Oh, Stephen P. Hunger, Allen Eng Juh Yeoh, Shawn HR Lee · 2025 · EJC Paediatric Oncology
73. Receipt of Alcohol Screening, Brief Intervention, and Treatment Among US Adults With and Without a History of Cancer
    Devon K. Check, Zhen Li, Sahar Shibeika, Caroline E. Sloan, Andrea Phillips Sitlinger, Leah L. Zullig, Solomon A. Graf, Dan V. Blalock · 2025 · JCO Oncology Practice
74. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic
    Lilian Hanna, Gordon Taylor Moffat, Wilma M. Hopman, Pierre-Olivier Gaudreau, Andrea S. Fung · 2022 · Cancer Treatment and Research Communications
75. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies
    Tomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yuki Sonoda, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa et al. · 2024 · Oncology
76. Real‐world treatment patterns and outcomes based on RAS / BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort
    Sietske C. M. W. van Nassau, Koen Zwart, Frederieke H. van der Baan, Geraldine R. Vink, Marloes A.G. Elferink, Pétur Snæbjörnsson, Anne Maria May, Miriam Koopman, Jeanine M.L. Roodhart · 2025 · International Journal of Cancer
77. Cost of Neoadjuvant Immunotherapy vs Up-Front Surgery in Cutaneous Squamous Cell Carcinoma
    Shannon S. Wu, Alexander Dimitrios Colevas, Luis F. Martinez-Ramirez, Uchechukwu C. Megwalu, Michelle Chen, A Atwell, Vasu Divi · 2025 · JAMA Otolaryngology–Head & Neck Surgery
78. Hospital Accreditation and Geographic Disparities in Timely Cancer Care
    Jason Semprini, Joshua W. Devine, Ingrid Marie Lizarraga, Mary E. Charlton · 2025 · Health Services Research
79. Validation of a Chemotherapy Toxicity Prediction Model in Older Adults With Cancer in Taiwan
    Chieh-Ying Chang, Yu‐Shin Hung, Ming‐Chung Kuo, Wen‐Chi Chou · 2025 · Cancer Control
80. Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug Delivery
    Robert S. Epstein, JoAnn Krenitsky, Phillip W. Sarocco · 2025 · Oncology and Therapy
81. The effect of tumor growth kinetics on survival and time toxicity after resection of recurrent glioblastoma
    Adeline L. Fecker, Cooper Stateler, Molly Joyce, Sidharth K. Sengupta, Hanna E. Minns, Joseph Girard Nugent, Jordan L. Smith, Seunggu Jude Han, Matthew D. Wood, Ahmed M. Raslan et al. · 2025 · Neurosurgical FOCUS
82. Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes
    Allison Mo, Erica M. Wood, Jake Shortt, Zoe McQuilten · 2025 · Transfusion
83. Drug dose optimization and substitutions to improve access for patients with gastrointestinal and neuroendocrine cancers
    Rachel P. Riechelmann, Tiago Cordeiro Felismino, B. Müller, Renata D’Alpino Peixoto, Daniel A. Goldstein · 2025 · ESMO Gastrointestinal Oncology
84. Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study
    Masanori Oshi, Tomo Nakayama, Ichiro Ota, Mahato Sasamoto, Akimitsu Yamada, Kazutaka Narui, Kazuaki Takabe, Itaru Endo · 2025 · Breast Cancer
85. Time toxicity associated with treatment of metastatic or unresectable gastro-oesophageal cancers in the second-line setting
    Rebecca Han Nguyen, Joanne Tang, Udit Nindra, Aflah Roohullah, Robert Yoon, Annette Tognela, Stephanie Hui-Su Lim, Ray Asghari, Wei Ming Chua, Weng Leong Ng · 2026 · Supportive Care in Cancer
86. Stakeholder Perspectives on the Term Time Toxicity to Describe Health Care Contact Time Associated With Cancer Treatments
    Samuel Xavier Stevens, Ella El-Katateny, Arjun Gupta, Richard De Abreu Lourenço, Joanne L Shaw, Christopher M. Booth, Janette L. Vardy · 2026 · JCO Oncology Practice
87. Planned time burden for patients participating in phase 2 cancer trials
    Charlotte Ouimet, Renata Iskander, Ryan David Nipp, Jonathan Kimmelman · 2026 · The Oncologist
88. Cancer CARE (Connected Access and Remote Expertise) Beyond Walls — Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy
    Roxana Stefania Dronca, Jeremy C. Jones, Michael J. Maniaci, Dina Elantably, Gina L. Mazza, Hemant S. Murthy, Tufia C. Haddad, Lucia Nolan, Jennifer L. Hunze, Deborah Fischer et al. · 2026 · NEJM Catalyst
89. Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis
    Muhammad Muntazir Mehdi Khan, Edward Anthony Joseph, Muhammad Anees, Erin E. Grayhack, Yue Yin, Paul B. Renz, Sricharan Chalikonda, David L. Bartlett, Casey J. Allen · 2026 · Annals of Surgical Oncology
90. Quantifying treatment-related travel burden and its association with mortality in pediatric cancer: An analysis of state cancer registry data
    Emma Hymel, Kendra L. Ratnapradipa, Cheng Zheng, Jenna Allison, Edward S. Peters, Sarah H. Nash, Mei‐Chin Hsieh, Shinobu Watanabe‐Galloway · 2026 · Cancer Epidemiology
91. Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter
    Samuel Xavier Stevens, Michelle Tregear, Rachel P. Riechelmann, Christopher G C A Jackson, Christopher M. Booth · 2026 · American Society of Clinical Oncology Educational Book
92. Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
    Ajay Major, Esprit Ma, Anthony S Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Avinash Pophali, Sally Werner, Rebecca Bungay, Dominick Latrémouille-Viau et al. · 2026 · The Oncologist
93. BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma
    Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis Alexander Eichenauer, A. S. Robertz, Janina Jablonski, Vincent Combüchen, Jan Oliver Staak et al. · 2026 · British Journal of Haematology
94. Quantity versus quality: Keys to adoptive cell therapy success in breast cancer
    Emil Lou · 2022 · Med
95. Pancreatic cancer: still a cold case?
    Michele Reni, Giulia Orsi · 2022 · The Lancet Oncology
96. Synthesis, ADMET Prediction, and Antitumor Profile of Phenoxyhydrazine- 1,3-thiazoles Derivatives
    Ana Cristina Lima Leite, Lucianna Râbelo Pessôa de Siqueira, Larissa Pelágia de Lima Ferreira, Gevânio Bezerra de Oliveira Filho, Marcos Victor Gregório de Oliveira, Aline Ferreira Pinto, Vanessa Gouveia de Melo Silva, Paulo André Teixeira de Moraes Gomes, Marcos Veríssimo de Oliveira Cardoso, Maria de Nazaré Correia Soeiro et al. · 2022 · Current Topics in Medicinal Chemistry
97. The dosimetric underpinning of bladder filling criteria for prostate image-guided volumetric modulated arc therapy
    Vickie C. Kong, Jennifer Dang, Vanessa Wan, Tara Rosewall · 2023 · British Journal of Radiology
98. Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity
    Manju Sengar, Wilma M. Hopman, Ghulam Rehman Mohyuddin, Aaron Michael Goodman, Bishal Gyawali, Deborah Mukherji, Nazik Hammad, Conjeevaram S. Pramesh, Ajay Kumar Aggarwal, Richard J. Sullivan et al. · 2023 · ecancermedicalscience
99. Population Preferences for Treatment in Life-Limiting Illness: Valuing the Way Time Is Spent at the End of Life
    Patricia M. Kenny, Deborah J. Street, Jane P Hall · 2025 · Medical Decision Making
100. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
     Jonathan Wadsley, Alan Christie, Roopinder Gillmore, Amy Trinh, Rachel Greig · 2023 · Drugs in Context